Literature DB >> 9641215

Predictors of co-incidental CIN II/III amongst a cohort of women with CIN I detected by a screening Pap test.

M A Duggan1, S E McGregor, G C Stuart, S Morris, V Chang-Poon, A Schepansky, L Honore.   

Abstract

Approximately 20-40% of lesions interpreted by a screening Pap test as CIN I and subsequently examined by colposcopy include a co-incidental CIN II/III. Since the HPV profiles of CIN I and CIN II/III differ, HPV typing may predict these co-incidental higher grade lesions. Based on both the colposcopic impression and repeat Pap test, 537 women referred for examination of CIN I as classified by a screening Pap test were triaged into group A (</= CIN I) or group B (>/= CIN II). Clinical, demographic, reproductive, and risk factor data was collected by questionnaire and HPV typing of cervical scrapes was done by PCR. Group A included 342 (63.7%) women and group B 195 (36.3%). Group B women more frequently were current cigarette smokers (p<0.001) and had a high school or lesser level of education (p=0.04). HPV positivity amongst younger group B women (</= 21 years) and a history of current/occasional cigarette smoking in those 22 years and older were significant predictors of triaged, co-incidental CIN II/III (p<0.001). This age restriction will limit the adoption of HPV testing as an universal, adjunctive test for the identification of CIN II/III amongst CIN I lesions detected by a screening Pap test. A greater health advantage may be gained by increasing women's awareness of the risks, including that of cervical cancer associated with cigarette smoking.

Entities:  

Mesh:

Year:  1998        PMID: 9641215

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  1 in total

Review 1.  Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis.

Authors:  Andrea C Tricco; Carmen H Ng; Vladimir Gilca; Andrea Anonychuk; Ba' Pham; Shirra Berliner
Journal:  BMC Infect Dis       Date:  2011-09-05       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.